Imidazopyridine derivatives which inhibit the secretion of gastric acid
    1.
    发明授权
    Imidazopyridine derivatives which inhibit the secretion of gastric acid 有权
    抑制胃酸分泌的咪唑并吡啶衍生物

    公开(公告)号:US08669269B2

    公开(公告)日:2014-03-11

    申请号:US13132564

    申请日:2009-10-27

    申请人: Mikael Dahlstrom

    发明人: Mikael Dahlstrom

    CPC分类号: C07D471/04

    摘要: The present invention relates to substituted imidazo[1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.

    摘要翻译: 本发明涉及式I的取代的咪唑并[1,2-a]吡啶,其中R是-CH 2 COOH或-COOH,其抑制外源或内源性刺激的胃酸分泌,并且可用于预防和治疗胃酸相关疾病 和胃肠道炎性疾病。

    Benzothiazepine derivatives
    2.
    发明授权
    Benzothiazepine derivatives 有权
    苯并硫氮杂衍生物

    公开(公告)号:US07192945B2

    公开(公告)日:2007-03-20

    申请号:US10451262

    申请日:2001-12-17

    IPC分类号: A61P3/06 A61K31/55 C07D281/10

    摘要: The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described

    摘要翻译: 本发明涉及式(I)的化合物:(其中可变基团如本文所定义)其药学上可接受的盐,溶剂合物,这些盐及其前药的溶剂合物及其作为回肠胆汁转运(IBAT)抑制剂用于治疗的用途 的高脂血症。 还描述了其制备方法和含有它们的药物组合物

    IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID
    5.
    发明申请
    IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID 有权
    抑制胃酸分泌的咪唑吡啶衍生物

    公开(公告)号:US20110237619A1

    公开(公告)日:2011-09-29

    申请号:US13132564

    申请日:2009-10-27

    申请人: Mikael Dahlstrom

    发明人: Mikael Dahlstrom

    CPC分类号: C07D471/04

    摘要: The present invention relates to substituted imidazo[1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.

    摘要翻译: 本发明涉及式I的取代的咪唑并[1,2-a]吡啶,其中R是-CH 2 COOH或-COOH,其抑制外源或内源性刺激的胃酸分泌,并且可用于预防和治疗胃酸相关疾病 和胃肠道炎性疾病。

    Pharmaceutically useful salts of carboxylic acid derivatives
    8.
    发明申请
    Pharmaceutically useful salts of carboxylic acid derivatives 审中-公开
    羧酸衍生物的药用盐

    公开(公告)号:US20060142389A1

    公开(公告)日:2006-06-29

    申请号:US10560657

    申请日:2004-06-16

    IPC分类号: A61K31/205 C07C229/34

    CPC分类号: C07C235/20 C07B2200/07

    摘要: A compound selected from one or more of the following: a (1R,2S)-2-hydroxyindan-1-amine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid; an L-arginine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino-2-oxoethoxyphenyl)propanoic acid; a tert-butylamine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino-2-oxoethoxyphenyl)propanoic acid; a choline salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid; an adamantylamine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid; a N-benzyl-2-phenylethanaminium salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid; a N-benzyl-2-(benzylamino) ethanaminium salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid; or a tris(hydroxymethyl)methylamine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid.

    摘要翻译: 选自下列一种或多种的化合物:(2S)-2-乙氧基-3-(4- {2- [己基(2-苯基乙基) 氨基] -2-氧代乙氧基}苯基)丙酸; (2S)-2-乙氧基-3-(4- {2- [己基(2-苯基乙基)氨基-2-氧代乙氧基苯基)丙酸的L-精氨酸盐; (2S)-2-乙氧基-3-(4- {2- [己基(2-苯基乙基)氨基-2-氧代乙氧基苯基)丙酸的叔丁基胺盐; (2S)-2-乙氧基-3-(4- {2- [己基(2-苯基乙基)氨基] -2-氧代乙氧基}苯基)丙酸的胆碱盐; (2S)-2-乙氧基-3-(4- {2- [己基(2-苯基乙基)氨基] -2-氧代乙氧基}苯基)丙酸的金刚烷基胺盐; (2S)-2-乙氧基-3-(4- {2- [己基(2-苯基乙基)氨基] -2-氧代乙氧基}苯基)丙酸的N-苄基-2-苯基乙胺盐; (2S)-2-乙氧基-3-(4- {2- [己基(2-苯基乙基)氨基] -2-氧代乙氧基}苯基)丙酸的N-苄基-2-(苄基氨基)乙胺盐; 或(2S)-2-乙氧基-3-(4- {2- [己基(2-苯基乙基)氨基] -2-氧代乙氧基}苯基)丙酸的三(羟甲基)甲胺盐。

    Alkylammonium salts of omepazole and esomeprazole
    9.
    发明申请
    Alkylammonium salts of omepazole and esomeprazole 失效
    奥美拉唑和艾美拉唑的烷基铵盐

    公开(公告)号:US20050182099A1

    公开(公告)日:2005-08-18

    申请号:US10506345

    申请日:2003-03-04

    申请人: Mikael Dahlstrom

    发明人: Mikael Dahlstrom

    CPC分类号: C07D401/12 C04B35/632

    摘要: The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to alkylammonium salt of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and an alkylamine with formula NR?1#191R?2#191R?3#191 wherein R?1#191 is a linear, branched or cyclic C?1#191-C?12#191-alkyl group, R?2#191 and R?3#191 are hydrogen. The present invention also relates to a process for preparing crystalline salts, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compound of the invention.

    摘要翻译: 本发明分别涉及奥美拉唑和艾美拉唑的新盐,即5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基) - 甲基]亚磺酰基] -1H-苯并咪唑的盐和 (S) - 对映体。 更具体地,本发明涉及通过奥美拉唑和埃索美拉唑的反应形成的化合物的烷基铵盐和具有式NR 1#191R 2#191R 3#191的烷基胺,其中R 1#191是线性的 ,支链或环状C 1〜19 C 18 -C 18烷基,R 2#191和R 3#191为氢。 本发明还涉及通过施用本发明的化合物制备结晶盐的方法,药物制剂和治疗胃相关疾病的方法。